Kedudukan dalam Saham
#24895
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Perubahan (1 tahun)
-28.94%
Perdagangan Orexo AB (ORX)
Harga ORX dengan permodalan pasaran b
Modal pasaran bagi Orexo AB(ORX)
Modal Pasaran: $55.01M
Sehingga August 2026, Orexo AB mempunyai modal pasaran sebanyak $55.01M. Ini menjadikan Orexo AB syarikat ke-24895th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Orexo AB dari 2005 hingga 2026
ORX berbanding dengan 5 teratas yang paling popular stocks
| Harga ORX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.257T
|
+9,556,678.03%
|
|
|
|
|
$4.599T
|
+8,360,093.75%
|
|
|
|
|
$4.107T
|
+7,465,529.21%
|
|
|
|
|
$3.577T
|
+6,503,225.57%
|
|
|
|
|
$2.807T
|
+5,103,486.09%
|
